Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of agrocybe aegerita galactose agglutinin to preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament

A lectin and application technology, which is applied in the field of pharmacological application of poplar mushroom galectin to achieve the effects of inhibiting infection, improving human immunity and reducing viral load

Inactive Publication Date: 2011-10-05
WUHAN UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no literature report that Populus galectin has pharmacological use against human immunodeficiency virus infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of agrocybe aegerita galactose agglutinin to preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament
  • Application of agrocybe aegerita galactose agglutinin to preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament
  • Application of agrocybe aegerita galactose agglutinin to preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0025] Experimental example 1 Anti-HIV infection activity experiment of fungal lectin AAL

[0026] Anti-HIV experiments include cytotoxicity experiments and anti-HIV replication experiments.

[0027] Cytotoxicity test (MTT assay): Culture C8166 cells (Wuhan Institute of Virology, Chinese Academy of Sciences) in 96-well plates (3×10 4 C8166 cells were treated with different concentrations (1.25nM, 6.25nM, 30nM, 150nM, 750nM) of fungal lectin AAL (SEQ ID No.2), each concentration repeated 3 wells, 37 ° C, 5% CO 2 After culturing for 4 days, the survival rate of the cells was detected by the MTT method. The concentration of drug that causes a 50% reduction in cells is the CC50.

[0028]HIV Replication Inhibition Assay: Parallel to the cytotoxicity assay, the HIV replication inhibition assay is detected by p24 antigen capture ELISA assay. C8166 cells inoculated with HIV-1 LAI (The virus comes from the Institute of Virology, Chinese Academy of Sciences), MOI of the virus = 0.05...

experiment example 2

[0032] Experimental Example 2 Effect of fungal lectin AAL on virus replication

[0033] Infection of HIV-1 in C8166 cells LAI Fungal lectin AAL (SEQ ID No.2) was added at different times (0 hour, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, 24 hours) after the virus, and the virus replication was detected according to the method in Experimental Example 1. The multiplicity of infection (MOI) of the inoculated virus was 0.05, the final drug concentration was 6.25nM, and the culture system was 300ul. Azidothymidine (AZT) was used as a positive control. See the experimental results figure 2 . The experimental results showed that the fungal lectin AAL had a similar inhibitory trend to the virus as AZT, but at the same concentration, the fungal lectin AAL had a better effect on inhibiting HIV replication than AZT.

experiment example 3

[0034] Experimental example 3 Inhibition of the fungal lectin AAL on the fusion of chronically infected cells and uninfected cells to form syncytia

[0035] In order to detect the inhibitory effect of fungal lectin AAL (SEQ ID No.2) on the formation of syncytia between chronically infected C8166 cells and uninfected C8166 cells, infected cells were mixed with different concentrations of AAL (SEQ ID No.2) (0.2nM, 1nM, 5nM, 25nM, 125nM, 625nM) for 1h, washed to remove excess AAL, and then added uninfected cells to the culture system, wherein the ratio of infected cells to uninfected cells was 1:8. After 36 hours of co-cultivation, the cells were observed and the syncytia were counted.

[0036] See the experimental results image 3 . From the experimental results, it can be seen that the fungal lectin AAL inhibits the formation of syncytia, and the EC50 is 1.73nM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of agrocybe aegerita galactose agglutinin to the preparation of an anti-HIV (Human Immunodeficiency Virus) infection medicament. As proved by a large quantity of experiments, a mycoagglutinin ALL (SEQIDNo.2) can effectively suppress the infection of HIV on C8166 cells, can specifically activate the activity of CD4<+>T lymphocytes without influencing CD8<+>T lymphocytes, has high activity on suppressing HIV infestation and stimulating the multiplication of CD4<+>T lymphocytes, can well meet the treatment indexes of reduction in the virus capacity and increase in CD4<+> cells during the treatment of HIV, and can be used for preventing and treating HIV. The invention further discloses an antibody specifically combined with the agrocybe aegerita galactose agglutinin and the application of a nucleotide for coding the agrocybe aegerita galactose agglutinin to the prevention or treatment of HIV infection.

Description

technical field [0001] The present invention relates to a new pharmacological application of fungal lectin, in particular to the pharmacological application of galectin isolated from the fungus Agrocybe aegerita in the prevention or treatment of human immunodeficiency virus (HIV) infection, belonging to The field of pharmacological application of poplar mushroom galectin. Background technique [0002] In the 25 years from the identification of HIV-1 to 2008, approximately 25 million people died of AIDS. According to the World Health Organization (World Health Organization) statistics in 2008, approximately 33.2 million people around the world are infected with human immunodeficiency virus (HIV), and it is estimated that 45 million new infections will appear between 2008 and 2010. On February 18, 2009, the Ministry of Health of China released a report on the AIDS epidemic. By the end of 2009, there were about 740,000 surviving HIV carriers and patients in China. In the first...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16C07K14/375C12N15/31G01N33/569A61P31/18A61P37/04
Inventor 孙慧李雅木陈义杰姜帅尹亚琳
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com